Allogeneic haematopoietic cell transplantation (HCT) is the most effective curative therapy in acute myeloid leukaemia (AML) and myelodysplastic syndromes (MDS). Incidence of AML and MDS increases with age, peaking in the seventh decade. Despite improved Ara-C and anthracyclin-based chemotherapy regimens, the prognosis of AML in patients beyond 60 years of age is dismal. The introduction of peripheral bloodderived stem cell grafts into allogeneic HCT and the known antileukaemic effect of donor lymphocyte infusions paved the way for reduced-intensity conditioning (RIC) allogeneic stem-cell transplantation, which makes transplant in advanced age possible and significantly reduces transplant-related organ toxicity and mortality. The success of RIC HCT relies on the alloreactivity of the donor immune system and the graft-versusleukaemia effect. We try to answer the following questions in this paper: who should receive RIC HCT? when and how should the transplant be performed? is there an upper age limit and what is the future of RIC HCT?
Introduction
Allogeneic haematopoietic cell transplantation (HCT) is the most effective curative therapy in acute myeloid leukaemia (AML) and myelodysplastic syndromes (MDS). In the early days, bone marrow transplantation was applied in young patients with refractory leukaemia resulting in the cure of some patients. 1, 2 Results have since improved via the administration of conventional high-dose AraC-based consolidation chemotherapy followed by allogeneic HCT in AML in first remission, with the result of around 50-60% of patients being cured. 3 The incidence of AML and MDS increases with age, peaking in the seventh decade. Despite improved AraC and anthracyclin-based chemotherapy regimens, the prognosis for AML patients above 60 years of age is dismal. Careful cytogenetic analyses performed within clinical trials revealed an independent negative effect of age beyond the known effects of specific cytogenetic abnormalities. [4] [5] [6] With the introduction of peripheral blood-derived stem cell grafts into allogeneic HCT and the known anti-leukaemic effect of donor lymphocyte infusions (DLI), the role played by the intensity of pretransplant conditioning was re-examined in the 1990s. Diligent investigations by Storb et al. 7 performed in the dog model without malignant disease established a lower limit of total body irradiation (TBI) of 2 Gy, and graftversus-host disease (GvHD) prophylaxis with Cyclosporin A and mycophenolic acid as sufficient for permanent engraftment of peripheral blood-derived, cytokine-mobilized haematopoietic stem-cell grafts, inducing a state of mixed chimaerism. 7 Several hundred patients have been transplanted successfully since then, and the risk of rejection has been further reduced by the addition of the T-lymphocytotoxic purine analogue fludarabine. 8 This 2 Gy-fludarabine conditioning regimen is a genuine immunosuppressive-only conditioning regimen with virtually no direct effect on malignant disease present at the time of conditioning. The success of allogeneic HCT must rely solely on the alloreactivity of the transplanted donor's immunosystem, and has been shown to be especially effective in patients with controlled disease, preferably those in remission. 9 Various regimens have since been developed applying moderate doses of chemotherapy or total body irradiation for conditioning. [10] [11] [12] [13] [14] [15] [16] Doses were often arbitrarily reduced from the 'standard high-dose' conditioning regimens such as busulfan (16 mg/kg body weight) or TBI (10-12 Gy) in combination with cyclophosphamide. These reduced-intensity conditioning (RIC) regimens have often been called 'nonmyeloablative' -a misnomer resulting in frequent misunderstanding and a linguistic Tower of Babel in the field of allogeneic haematopoietic cell transplantation. However, RIC has made allogeneic HCT more feasible in patients previously not considered candidates for this curative therapy, as RIC has ensured engraftment, usually induced a state of mixed or full donor chimaerism and has substantially reduced transplantrelated organ toxicity. [10] [11] [12] [13] [14] [15] [16] RIC opened the eyes of colleagues unfamiliar with this complex therapy, and a rush of referrals for 'mini-transplants' was anticipated.
Nowadays patients older than 60 years of age are regularly transplanted from related and, increasingly, from unrelated donors. We nowadays make decisions in clinical situations that were unimaginable until the late 1990s. Especially in AML and advanced MDS in the elderly, the question is raised whether to go for standard induction chemotherapy, or proceed with allogeneic HCT right away. Even the statement 'this patient is too sick for induction or consolidation and would be better off with an allogeneic transplant right away' reflects this novel attitude towards allogeneic HCT.
When interpreting results and planning new strategies in allogeneic HCT, we must remember that the conditioning regimen's intensity is only one part of the story. Large data compiled in international transplant registries such as the EBMT and CIBMTR indicate that death due to toxicity contributes to about 10% of failures after allogeneic HCT. 17 Whereas the reduction in conditioning intensity is a prerequisite for its wider application in frail or elderly patients, we must remain focused on the implications for the changing immunosystem, with opportunistic infections and graft-versus-host reactions as major complications, as well as on reducing relapse rates. The latter problem cannot be solved by simply applying arbitrarily reduced doses of chemotherapy. We should instead make use of drugs with antileukaemic and immunosuppressive properties within the conditioning regimen in the most intelligent manner.
However, age has been a limiting factor for the widespread application of allogeneic HCT, since high-dose radiation and or chemotherapy-induced toxicity and, moreover, the risk of severe GvHD increasing with age have been considered prohibitive in patients over a certain age limit. Allogeneic transplantation for patients above 30 was innovative in the 1980s 18 and until the 1990s, 50-55 years of age was the upper limit for matched sibling and unrelated-donor HCT. RIC is routine in current allogeneic transplantation. We are now able to transplant patients who had to be excluded previously because of clinical judgments regarding comorbidities or age.
The issues presently in RIC allogeneic transplantation are who, with special consideration of age, when and how.
Who should receive standard-dose conditioning, and are there lower and upper age limits for RIC? Is there a biologically defined age limit? Is there a need for geriatric or comorbidity assessments?
When we speak of 'elderly' patients in allogeneic HCT nowadays, we must be aware that this term has not been clearly defined. Noteworthy are the facts that patients above 75 years are defined as geriatric, and those 60-65 years are not regarded as old in medicine outside allogeneic HCT. The current upper age of patients undergoing successful allo-HCT, especially with grafts from unrelated donors, is around 75 years of age. 9, 19 Although few investigators have reported results with standard high-dose conditioning in patients with leukaemia older than 60 years, treatment-related mortality rates up to 50% appear to be prohibitive. 20, 21 Age limits have been defined somewhat arbitrarily, and especially in unrelated donor transplantation, an age limit lower than in sibling donor transplantation was frequently chosen, without a scientific basis. There is no definition as to what the valid upper age limit is for standard conditioning, or what the lower limit for RIC is. Rather, should we focus on the results of specific conditioning protocols obtained in each disease and state of remission. To reduce toxicity, standard high-dose conditioning regimens are applied up to the age of 50-55 years in most centers, with RIC beyond that age range and no upper limit for otherwise-fit patients. With specific RIC and GvHD prophylaxis strategies in patients with AML/MDS older than 60 years transplanted from unrelated donors, TRM due to infections, organ toxicity, or GvHD is about 20%, similar to what is seen in young adult patients with the same disease-risk profile. 19 Should we use RIC in younger patients fit for standard high dose conditioning? Should RIC be used according to the underlying disease's relapse risk?
The current official answer to these questions is 'no', unless the patient, although young, is ineligible for standard conditioning, or underwent previous HCT, at least a recent one. However, these may be two of the more important questions in the field, since the lower risk of acute toxicity, as well as long-term sequelae like permanent infertility after RIC HCT, make this approach appealing to young patients. We should combine our efforts and focus on a phase III comparison of a specific RIC with standard-dose conditioning. Until then, young and fit patients up to the age of 50-55 years should receive full-dose conditioning.
There are still no definite answers regarding differential indications for RIC depending on the risk of relapse. Dose does appear to matter, at least in patients with leukaemias not in remission, since a regimen containing fludarabine, cytarabine and idarubicin (regarded as 'truly non-myeloablative' by the authors) resulted in excessive relapse of 460% and rejection rates compared to fludarabine and melphalan after SCT from sibling donors. 22 Results with specific RIC protocol and GvHD prophylaxis combinations for specific disease stages must be determined before final judgements can be made on the use of RIC in comparison to standard-dose conditioning. In view of those results, we then may proceed to define further lower age limits for RIC, or we may even conclude that specific RIC protocols in combination with peripheral blood-derived stemcell grafts are as good or better than traditional conditioning regimens, due to less organ damage, for example, of bone marrow stroma. 23 RIC already has its place in second transplantation for patients relapsing after autologous or allogeneic HCT, since allogeneic HCT is the only chance of cure for such patients, in whom standard high-dose conditioning confers inacceptable toxicity. 24 Age -no longer a factor deciding for or against HCT? With respect to an upper age limit for allogeneic HCT, we now have to rely on clinical judgment, since none of the available geriatric assessment tools or comorbidity scores (such as the Charlson comorbidity index) has been prospectively validated in this context. 25, 26 HCT from related and unrelated donors up to the age of 60 is now common practice in many centres, and patients well beyond 70 years of age are being transplanted successfully from allogeneic donors. 9, 19 However, owing to the dismal outcome associated with conventional chemotherapies, 6 every patient older than 60 years of age with AML or MDS should be informed about the possibility of allogeneic HCT after RIC, and donor searches should be initiated as early as possible, for example, at initial diagnosis.
When
The timing of allogeneic HCT has been addressed in standard conditioning for leukaemia patients. The number of chemotherapy cycles needed to reach CR is an independent risk factor for relapse in AML. For allogeneic HCT in first CR, increasing the number of pre-transplant consolidation chemotherapies has no benefit, and transplantation as early as possible with one consolidation therapy after reaching CR is a valid recommendation. 27 This most likely applies to standard-risk patients and may not necessarily be optimal for high-risk patients.
What about patients with AML or MDS unlikely to reach CR after induction chemotherapy?
If allogeneic HCT is already being planned, do those patients need pretransplant consolidation chemotherapy? Allogeneic HCT as soon as possible after initial diagnosis of high-risk patients results in a 2-year DFS of 60% when performed in aplasia after induction or first consolidation chemotherapy. 28 A rapid donor search initiated immediately at primary diagnosis, and efficient logistics (especially in unrelated donor transplantation) is of utmost importance with this approach. The inherent difficulties with an early-search strategy in poor-risk AML patients reaching first CR are reflected by results from the Anderson Cancer Center. 29 The combination of reducing the tumour cell burden by conventional chemotherapy, rapidly followed by additional cell reduction induced by reduced-intensity conditioning and cytokine-mobilized peripheral blood-derived stem-cell grafts from related or unrelated donors, appears to be highly effective and should be further explored within current AML trials. 30 The restriction of allogenic HCT to matched-sibling donor HCT alone is no longer justified with novel, efficient GvHD prophylaxis and improved HLA typing. Furthermore, results after standard-dose conditioning and unrelated donor HCT are at least as good as sibling-HCT, and may be even better in highrisk patients. 31 Results obtained with fludarabine and 2 Gy RIC in unrelated donor transplantation showed similar results. 9 What about allo-transplantation -especially with RIC -in relapsing patients?
Although reaching pre-transplant CR suggests a better postallo HCT outcome, restricting allogenic HCT to CR2 patients will lead to the failure to offer allogenic HCT to most patients, denying them thus a curative chance. However, data obtained in standard-dose conditioning have revealed no difference in outcome for relapsing or CR2 patients. 32 One valid strategy is to plan salvage chemotherapy within the context of allogeneic HCT. A readily available donor is of obvious benefit in such a situation, and we start a donor search for every patient with AML or MDS at initial diagnosis in our centers. Once a donor has been found, the transplant should be organized at time of relapse so that allogeneic HCT can take place 3-4 weeks after relapse chemotherapy. This strategy makes allogeneic HCT feasible in virtually all patients, either when reconstituting with normal haematopoiesis and reaching CR, or in persisting neutropenia or even persisting leukaemia. Longer-lasting periods of neutropenia are avoided with this approach. In addition we recommend prophylactic antifungal strategies, especially those directed against Aspergillus species. In patients with little likelihood of reaching a second CR, waiting until conditioning for transplant, or the above-mentioned sequential approach with short induction chemotherapy followed by RIC the following week is recommended. 30 
How
Has a standard RIC regimen been established, and should we randomize different regimens?
In an attempt to group systematically the variations on the theme RIC, the EBMT has defined RIC as any regimen equalling 50% or less of a standard conditioning regimen, the latter defined as 16 mg/kg busulfan (oral preparation) or fractionated 12 Gy TBI in combination with cyclophosphamide or VP16 for leukaemias, and 200 mg/m 2 melphalan for multiple myeloma. However, we must remember that these dose limits were only defined for the purpose of grouping transplanted patients within registry data evaluations reflecting common practise, and they are not based on scientific evidence from clinical trials. Furthermore, when comparing results after RIC to 'standard high-dose' conditioning, especially within registry data, we should be conscious of an inherent bias due to the different type of patients and diseases treated, as well as centre-specific protocol variations under the RIC label. [33] [34] [35] A strict focus on conditioning only neglects other important outcome relatedaspects after allogeneic HCT, such as the type of GvHD prophylaxis, any treatment purposely given the week before conditioning and the use of DLI as part of the protocol, 30 to address just a few of the relevant aspects.
Alkylating agents are frequently combined with fludarabine as a lymphotoxic drug. However, its use within a regimen does not automatically make the regimen RIC. Combinations with two alkylating agents such as melphalan and thiotepa plus fludarabine (as used for haplo-transplantation) are especially myeloablative, although less toxic than TBI-based regimens. These protocols regularly achieve complete donor chimaerism in most patients. There has been a call for uniform RIC. However, rapid change in this field is reflected by frequent modifications of chemotherapy dosing in the RIC regimen, as well as variations in GvHD prophylaxis, the former due to higher than expected relapse rates or rejection, the latter because of problems with GvHD or infections, according to reports from individual transplant centres. 12, 36, 37 Where do we go from here? Various RIC regimens have demonstrated feasibility. A clear, randomized comparison of regimens is warranted based on well-designed phase-II trials with large enough patient cohorts. Novel drugs like intravenous busulfan preparations or treosulfan have been introduced in the field of RIC, and optimal dosing and combinations of these promising agents must be determined. 15, 38 However, with the current restrictions involving investigator-initiated trials in most European countries and a lack of interest on the part of the pharmaceutical industry, there is a shortage of funds for the execution of such trials. An alternative may be found in a matched-pair analysis within registries and AML trial groups.
GvHD
Previous registry data show an increased risk of GvHD with age: is there a need for 'age-, RIC-adapted' GvHD prophylaxis? RIC is attractive due to its low acute toxicity, but it must be combined with peripheral blood-derived grafts with their rich supply of effector cells. Randomized trials in sib-HCT have shown a higher incidence of mild acute and, even more important, a significant increase in extensive chronic GvHD. 17, 39, 40 This may explain why very intensive GvHD prophylaxis regimens containing high doses of alemtuzumab or ATG or intensive T-cell-depleted grafts were used initially.
Whereas early follow-up demonstrated promising results with little acute GvHD, excessive relapse rates and the cumulative risk of deadly infections from viruses and fungi have led these regimens be modified. As often happens with trends, initial high expectations are often unfulfilled.
Owing to uncritical data interpretation, and coming after the initial euphoria, allogeneic HCT is now often criticized as being inefficient in various diseases. However, if low-dose conditioning is combined with low T-cell numbers in the graft, for example due to T-cell depletion by CD34 þ selection and high doses of immunosuppression in patients with active or advanced malignancies, there is hardly any residual allo-effect and the patient is left in a vulnerable state of immuno-incompetence, plagued by opportunistic infections and with no malignancy control. 41 These 'no-dose' concepts, that is, the belief that one can cure leukaemia with mild conditioning and very little alloreactivity, should be restricted to exceptional clinical situations and not be used to discredit the high efficacy of allogeneic HCT.
As is the case in the general field of allogeneic HCT, GvHD is also of concern in RIC. A novel clinical course was observed with frequent late-onset acute GvHD beyond the first 3 months, and the time period for tapering the immunosuppression appeared to be particularly risky. 42 Furthermore, in response to the mixed chimaerism often observed after less intensive RIC allo-HCT, DLI are given prophylactically or at time of relapse, accompanied by the considerable risk of inducing severe acute GvHD grade III-IV in 10-20% of patients. 43 We need preferably randomized trials with special focus on the prophylaxis of extensive chronic GvHD. The problems presented by the 'changing immuno system' do not necessarily seem to depend on the conditioning regimen or be agedependent. At least some degree of controlled chronic GvHD has been shown to have a positive influence on survival in acute leukaemia patients.
Should the type of donor, related or unrelated, influence the indication for allogeneic HCT?
With adequate GvHD prophylaxis, allogeneic HCT results from unrelated donors are as good as those after matched sibling-HCT. 31 When dealing with elderly patients, we are frequently confronted with frail siblings with comorbidities. A young unrelated donor may be a safer option than an old sibling with respect to stem-cell donation in such situations, and be even better for the patient with the potentially higher stem-cell count in the G-CSF-mobilized graft. The unrelated donor may confer a better allo effect, which is preferable in this patient group with high-risk, refractory MDS or leukaemia with high marrow blast counts or circulating blasts and results in cure rates 450% in combination with alkylating agent based RIC. 16, 19 Moreover, the biologically-young donor cells may benefit the recipient in the long run with less senescence and lower risk of oncogenic transformation.
The upper donor age for reasonable stem-cell mobilization is likely to be in the early eighth decade. Nucleated cell dose seems to matter, with significantly better outcome and higher cell counts in the graft from sibling donors after RIC in patients with advanced AML. 44 Faster immuno reconstitution and less mixed chimaerism, 45 as well as better survival 19 were observed in unrelated HCT after RIC in elderly patients with active AML or MDS receiving peripheral blood-derived stem-cell grafts containing CD34 cells/kg above the median of the patient series.
Is there a place for alternative stem-cell sources? Other rapidly evolving areas of clinical research are haplo and cord blood transplantation. Numerous reports indicate that radiation-free RIC protocols can be used in both approaches for successful transplantation. For elderly patients lacking a related or unrelated donor, double-cord blood transplantation may be an alternative, the oldest patient thus treated and registered in the Eurocord database was 69 years old (E Gluckman, EBMT meeting, 2007). However, there is a lack of definite data.
What is the future of RIC?
As mentioned above, the use of RIC is common place in many transplant centres. [10] [11] [12] [13] [14] [15] [16] RIC's emergence has facilitated the ever-widening application of allogeneic HCT, with this curative approach being integrated earlier within treatment protocols for leukaemia and myelodysplasia. We will likely abandon the use of the term RIC, preferring to employ specific protocols. This will be the only means of demonstrating clear treatment results in allogeneic HCT. The GvHD prophylaxis protocol is almost as important as the doses used for conditioning, in addition to the other factors mentioned above.
Age should not be the sole factor in the decision for or against allogeneic HCT. A patient with AML regarded as fit for induction chemotherapy is a candidate for allogeneic HCT. In fact, some patients, for example those with MDS, are better off going straight to transplant instead of undergoing induction chemotherapy. The early search for a donor and a rapid allogeneic HCT are absolutely key to survival in high-risk AML patients older than 50 years. 29 Current randomized trials are addressing the role of allogeneic HCT with RIC in first CR (OSHO, HOVON, CIBMTR). However, most AML and MDS patients older than 50-60 years will not reach CR1 and these patients need an early allotransplant. As we have learned from treating elderly patients with high-grade lymphomas, we should not be afraid to administer adequate doses of chemotherapy. Excessive relapse rates of more than 60% in elderly patients with active leukaemia have been witnessed with the use of less intensive RIC regimens and intensive GvHD prophylaxis protocols, and frequent mixed chimaerism cannot be easily overcome by DLI. 14, 36 The conditioning dose seems to play an important role, at least in AML or MDS patients with excessive blasts in marrow or peripheral blood at the time of transplant -RIC protocols with single low-dose alkylating agents like low-dose melphalan have resulted in survival rates well below 10%. 22, 35, 38 In contrast, somewhat more intensive RIC containing two alkylating agents in combination with unrelated donor-derived PBSC grafts resulted in 3-year EFS of 53% and a relapse rate of 27% in elderly chemorefractory AML patients. 19 In terms of allogeneic HCT, this means that adequately dosed conditioning with agents effective in killing malignant stem cells is probably better for patients with active leukaemia than the lowest possible conditioning facilitating engraftment and requiring further therapies such as DLI.
The current upper age for allogeneic HCT depends on individual clinical judgment and the RIC protocol in use; any limit is arbitrary. Every patient older than 50-60 years of age with AML or MDS regarded as fit for induction chemotherapy should be informed about the possibility of allogeneic HCT after RIC. Donor searches, including unrelated donors, should be initiated as early as possible, preferably at initial diagnosis. With current approaches a considerable fraction of these patients, even those with chemorefractory disease, can be salvaged by adequately dosed RIC and allogeneic HCT. High-risk cytogenetic or molecular features of AML/MDS, induction failure, or chemorefractory disease are reasons for rapid allo-HCT. Factors that have to be optimized are type of RIC, GvHD prophylaxis as well as pre-and post-transplant measures; strategies are likely to vary from disease to disease. This is obviously a rapidly developing and progressing field of endeavour. Many of the important questions can now only be answered with 'we don't know'. That is why large-scale trials with specific RIC and GvHD prophylaxis protocols for specific diseases and states of remission should be performed.
